PBM 2.0: Evolution or Revolution

Specialty drug spending is skyrocketing with no end in sight and almost half of it is billed to the medical rather than the pharmacy benefit. At the same time, the average annual retail cost of a specialty drug now exceeds the median U.S. household wage. The momentum is undeniable and it is creating pressure on the industry status quo. Change is inevitable, but the key question remains at what speed will change take hold.

As specialty drugs drive up the cost of healthcare and in response, plan sponsors must increase controls to limit utilization of these drugs. While that sounds simple, it is a difficult decision.

In this webinar, PSG experts Kevin Host and Renee Rayburg will discuss how specialty drugs are fundamentally changing pharmacy management for plan sponsors.